Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer
: EGF, NRG1 and HGF reversed AZD4547-induced cell cycle arrest in SNU-16 cells. Cells were exposed to AZD4547 (10 nM), AZD4547 and ligands (50 ng/mL) or AZD4547, ligands and second RTK inhibitor (10 M) for 72 hours and then analyzed for their cell-cycle distribution using flow cytometry. PF, PF04217903; ERL, erlotinib. Data are represented as mean ± SD. *, p < 0.001
